1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Intervacc AB

Intervacc AB

SSTO:IVACC
0.83
SEK
-0.01
(-1.19%)
-0.27EPS
444.42MMarket Cap
Nov 12Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.48
2.8
3.58
2.22
0.87
0.23
0.08
0.08
0.14
0.09
0.13
0.07
0.05
Basic EPS, GAAP
0.42
0.01
-0.44
-0.59
-0.67
-0.53
-0.41
-0.44
-0.95
-1.17
-0.86
-0.27
-0.27
Free Cash Flow per Basic Share
- -
-0.85
-1.07
-1.49
-0.69
-0.8
-0.34
-0.4
-1.06
-0.53
-0.61
-0.23
-0.22
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
6.59
8.16
8.4
7.34
3.77
3.78
5.02
4.58
3.69
2.7
1.84
0.81
0.68
Tangible Book Value per Share
-0.56
0.74
0.66
1.71
1.08
0.87
2.42
1.74
1.1
0.95
0.3
0.46
0.34
Basic Weighted Avg Shares
22
22
16
22
41
53
63
67
68
88
88
297
341
Sales/Revenue/Turnover
78
63
56
48
36
12
5
5
10
8
12
20
18
Operating Margin (%)
12.95
3.31
-13.31
-28.5
-86.85
-229.41
-537.15
-560.83
-665.15
-1,167.55
-655.61
-415.7
-519.82
Depreciation Expense
6
6
6
6
15
6
6
6
21
25
19
19
19
Net Income, GAAP
9
- -
-7
-13
-27
-28
-26
-29
-64
-103
-76
-81
-92
Effective Tax Rate (%)
2.86
89.36
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
11.94
0.22
-12.25
-26.6
-77.22
-229.77
-535.59
-560.48
-662.52
-1,283.24
-640.66
-402.32
-506.51
Working Capital
2
19
13
32
43
39
151
105
62
83
26
156
115
LT Debt
- -
- -
8
1
1
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
102
127
130
165
190
220
338
308
250
238
162
275
233
Return on Invested Capital (%)
- -
0.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
0.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
0.12
-5.3
-8.65
-15.47
-13.6
-9.19
-9.1
-22.98
-42.14
-37.73
-36.97
-32.89

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
341
341
341
Market Capitalization
315
281
444

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
175
160
148
Cash, Cash Equivalents & STI
161
146
128
Accounts Receivable, Net
1
- -
- -
Inventories
10
10
12
Total Current Liabilities
19
25
33
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.92%
1.03%
69.35%
Free Cash Flow
26.85%
39.99%
24.75%
Net Income, GAAP
-465.95%
34.78%
7.02%
Sales/Revenue/Turnover
1.71%
38.93%
70.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
3
3
4
12
2025
5
7
5
3
20
2026
3
6
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.2
-0.25
-0.2
-0.86
2025
-0.08
-0.05
-0.04
-0.1
-0.27
2026
-0.06
-0.06
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Carl-Johan Dalsgaard
Full Time Employees
16
Sector
Health technology
Industry
Biotechnology
Address
Västertorpsvägen 135 Stockholm AB Sweden 129 44
IPO Date
Apr 7, 2017
Website
intervacc.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Intervacc AB (publ) is a Swedish biotechnology company dedicated to advancing animal health through the discovery and development of innovative vaccines against bacterial infections. The company leverages a proprietary technology platform centered on recombinant proteins to create safe and effective preventative solutions. Its primary commercial offering, Strangvac, is a vaccine for equine strangles, a highly contagious streptococcal infection affecting horses. Strangvac is approved across the European Union, the United Kingdom, and other European markets, with active distribution in numerous countries and aspirations for broader international reach, including the United States. Intervacc recently extended its significant distribution agreement with Dechra Pharmaceuticals for Strangvac by two years. Beyond its flagship product, Intervacc maintains an active research pipeline, including INV274, a vaccine candidate targeting Streptococcus suis infections in piglets, a project that has received Eurostars 3 grant funding. The company also previously pursued a vaccine candidate, INV412, against Staphylococcus aureus infections causing mastitis in dairy cows, though this project has been paused. Supplementing its vaccine development, Intervacc operates through subsidiaries such as Nordvacc Läkemedel AB, which markets and distributes veterinary pharmaceuticals and vaccines across Nordic and certain European markets, and Mybac-Vettech AB, an ISO-certified laboratory providing specialized diagnostic services in veterinary bacteriology and mycology within Sweden. The company has successfully secured substantial financing through a recent rights issue to fuel its growth initiatives, including the acceleration of Strangvac sales and the progression of its pipeline. Intervacc is headquartered in Hägersten, Sweden.